Ovid Therapeutics
OVID
OVID
48 hedge funds and large institutions have $54.5M invested in Ovid Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
–
Holders Change %
0%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
20
Reduced
11
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$2.08M |
| 2 |
BlackRock
New York
|
+$939K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$345K |
| 4 |
State Street
Boston,
Massachusetts
|
+$273K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$212K |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$903K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$556K |
| 4 |
Millennium Management
New York
|
-$346K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$302K |
